2008
DOI: 10.1016/j.jsat.2007.10.007
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of opioid-dependent pregnant women: Clinical and research issues

Abstract: This article addresses common questions that clinicians face when treating pregnant women with opioid dependence. Guidance, based on both research evidence and the collective clinical experience of the authors, which include investigators in the Maternal Opioid Treatment: Human Experimental Research (MOTHER) project, is provided to aid clinical decision making. The MOTHER project is a double-blind, double-dummy, flexible-dosing, parallel-group clinical trial examining the comparative safety and efficacy of met… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
169
0
1

Year Published

2013
2013
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 169 publications
(171 citation statements)
references
References 103 publications
(85 reference statements)
1
169
0
1
Order By: Relevance
“…Both methadone and buprenorphine are listed by the World Health Organization (WHO) as essential medications to treat OUD; in the United States, both are approved by the US Food and Drug Administration (FDA) for the treatment of opioid dependence/addiction. Methadone and buprenorphine have been shown to increase adherence to antiretroviral therapy in HIV‐infected drug users9 and to increase treatment retention of opioid‐dependent pregnant women 10. Recently, longer‐acting formulations of buprenorphine have been developed, including a monthly injection.…”
Section: Introductionmentioning
confidence: 99%
“…Both methadone and buprenorphine are listed by the World Health Organization (WHO) as essential medications to treat OUD; in the United States, both are approved by the US Food and Drug Administration (FDA) for the treatment of opioid dependence/addiction. Methadone and buprenorphine have been shown to increase adherence to antiretroviral therapy in HIV‐infected drug users9 and to increase treatment retention of opioid‐dependent pregnant women 10. Recently, longer‐acting formulations of buprenorphine have been developed, including a monthly injection.…”
Section: Introductionmentioning
confidence: 99%
“…Additional opioid will be required for any postoperative pain, as with any opioid-tolerant patient, and the infant will require high-level neonatal care because of the risk of withdrawal (Ludlow et al, 2007;Jones et al, 2008). Opioid requirements during labour may not be significantly increased although methadone-maintained patients in this study did have higher pain scores .…”
Section: Management Of Acute Pain In Pregnant Patients With An Addictmentioning
confidence: 84%
“…Opioid requirements during labour may not be significantly increased although methadone-maintained patients in this study did have higher pain scores . Those taking buprenorphine will also have higher opioid requirements after surgery, and the newborn is still at risk (albeit maybe a lower risk) of withdrawal (Ludlow et al, 2007); again, opioid requirements during labour may not be increased (Jones et al, 2008). Both methadone and buprenorphine should be continued without interruption or, if the patient cannot take oral medications, then an alternative route (or opioid) should be used (Jones et al, 2008).…”
Section: Management Of Acute Pain In Pregnant Patients With An Addictmentioning
confidence: 99%
“…It is widely believed that intrauterine death or fetal compromise is due to the "bingeing" or drastic fluctuations in serum levels of opiates or cocaine associated with "street" use [12]. Methadone substantially minimizes the peak and trough in maternal serum opioid levels that typically occur with repeat use of short-acting opioids such as heroin, thereby reducing the harm that the fetus encounters as a result of repeated intoxication and withdrawal [13]. Methadone use during pregnancy has been associated with improved prenatal care, [14] longer gestation, [15] higher birthweight, [16] and increased rates of infants discharged home in the care of their mothers [17].…”
Section: Introductionmentioning
confidence: 99%